Index

Note that figures are indicated by an italic f and tables are indicated by an italic t after the page number.

Ability-to-pay, 17–19, 21, 41–42. See also Market rationing
Accident victims, 59
Administrative rationing mechanisms, 106–109, 110. See also Formulary committees; Utilization reviews
physician advocacy role and, 133–134
Adverse selection, 44
Advocacy role of physicians, 101–102, 109, 112–113, 138–139, 147–148. See also Physicians’ decisions
Affordability vs. efficiency, colon cancer screening example, 24–26, 27, 37–38
Age-based rationing, 93
Agency for Health Care Policy and Research, 38–39
AIDS, 59, 78, 173, 174, 182
Alcohol abuse, 16–17, 182
Allocation decisions, 92–93, 94 distinguished from bedside rationing, 19–21
re scarce organs for transplants, 22, 81–85, 118
American Cancer Society, 131, 132
American with Disabilities Act, 76, 161
American Medical Association, 131
Angina treatment, 78
Antibiotics, 117–118, 134
Antigen matching, 62–63
Arthritis, degenerative, 39, 47
Asch, David, case vignettes survey, 126–128
Back pain, 36
Bedside rationing
alternative characterizations of, 125, 129, 135, 136
arguments for appropriate, 138, 139, 142, 146–149, 150–151
conditions defining, 111, 122–124, 123f
physician controls resource, 112, 120–122, 123f, 124
serving financial interest other than patients, 112, 117–120
withholding treatment in best interests of patient, 111, 114–116, 122–123, 123f
cost-effectiveness analysis (CEA) and, 97
debate over appropriateness, 125, 127–128, 128f, 137
Bedside rationing (cont.)
discriminatory potential, 103–104, 110
external standards or agents and, 130–133, 176–177
moral values and, 101, 102, 144–145, 146–147
physician-patient relationship and, 102–103
physicians’ advocacy role and, 101–102, 109, 112–113, 138–139, 147–148
physician training in, 103, 109, 118, 143–144, 178
traditional prohibitions against, 99–100
whether savings benefit patients, 105, 110, 112, 117–120, 123, 123–124, 130, 145–146 (see also Patient care vignettes)
Bioethics group members study (Ubel), 79–81
Blood products, 179–180
Blood test study, 93
Calabresi, G., and P. Bobbit (1978) Tragic Choices, 20–21
Callahan, Daniel, 32
Cancer. See Cervical cancer screening; Colon cancer screening
Capitation payments, 107, 109, 120, 177
Certificate of need laws, 106
Cervical cancer screening, 5–6, 131, 141–142
Cervical cancer screening vignette (Ubel), 126–128, 128f
Children, illnesses affecting, 56
Cholesterol-lowering drugs, 100, 180
Cigarette smokers, 85
Cleft lips, patients with, 59
Clinical pathways, 107, 108, 109
Clinicians’ decisions. See Physician decisions
Clinicians’ decisions. See Physician decisions
“Closed systems,” 130
Clot-busting drugs, 112
Coby Howard story, 3–4, 18, 22, 46
Colon cancer screening, 23, 24–26, 37–38, 141
vignette studies, 79–81, 81f, 87–91, 88f, 90f
Colon cancer screening vignette (Ubel), 79–81, 81f, 87–91, 88f, 90f
Community values on health care rationing. See Public’s health care priorities
Computer reminder systems, 108
Consumer choices, 48
Contrast agents, 120, 129–130
Copayments, patient, 42–43, 144
Cosmetic surgery, 26–27, 29, 56, 59
for breast reconstruction, 58
Cost-beneﬁts analysis (CBA), 67–68
Cost containment, 3, 11, 30, 37, 183. See also Allocation decisions budgeting, 177
considering costs is not necessarily rationing, 114–116, 121, 135–136
price reduction, 37–40
public preference for, 57, 67
wasteful practice elimination, 11, 37–40, 115
Cost-effectiveness analysis (CEA), 1, 3, 40, 46, 55–56, 160, 172. See also QALY (Quality-adjusted life-year); Utility assessment bedside rationing and, 100–101, 151
discriminatory aspects, 76–78
favoring present over future benefits, 158–161, 160f
the future of, 153, 171–174, 181–183
incorporating societal values (proposed), 157, 161, 163f, 163–168, 165f
Oregon Medicaid Program’s experience with, 4–5, 6, 7–10, 33, 46, 47, 52, 53, 75, 161
positive values of, 5–7, 159–161
public rejects as sole allocation
method, 85, 94
undervaluing public’s priorities, 35, 47–50, 53–56, 55, 55–56, 85, 155, 156, 172, 178
Cost of health care, 39–40, 145, 146
health insurance impacting, 32
technology driving, 32–33
Critical care professionals study, 56, 57
CT scans, 130–131
Diabetes, 134, 173
Diagnostic tests. See Screening tests
Disability-levels scale, 70–71, 71f
Disabled persons
cost-effectiveness analysis and, 85, 156, 161–163, 162f, 163f, 178
public’s preference for nondiscrimination against, 76–77, 77f
Discretionary services, noncoverage of, 42–43, 45
Discrimination
against chronically or seriously ill people, 85, 156, 178
against disabled people, 85, 156, 161–163, 162f, 163f, 178
against minorities, 62–63, 85, 103–104, 182
bedside rationing and, 103–105, 110
cost-effectiveness analysis and, 76–78, 161, 178
public views against, 76–78, 77f, 85, 161
Distributional equity. See Equity, distributional
Domestic violence screening, 142
Drugs, new, 106, 114–115, 173–176
Economic rationing. See Market rationing
Eddy, David, xiii–xiv, 126
Efficiency. See Health utility maximization
Emergency treatment, 28
Equity, distributional
difficulty in measuring, 86–88, 169–171
vs. efficiency, 78–85, 79–81, 81f, 86, 88f, 89–91, 90f
population covered (entire vs. partial), 87–88, 89–91, 90f
public preference for, 78–79, 85, 156
redistribution schemes and, 86
withholding existing treatments and, 86
Evans, Roger, 19–21
Expert panels, 24, 26
Explicitness
vs. implicitness in defining rationing, 1, 10, 13, 14f, 15f, 16–19, 17f, 29, 75f
limiting services and, 122, 176–177
of Oregon Medicaid program’s list, 10, 19, 100
Fairness, 67, 94. See also Discrimination; Equity, distributional
public views of, 85–86
unwillingness to abandon patients, 92–93
False positive results, 116
Feedback mechanisms, 107, 108, 109
Fee-for-service reimbursement, 109, 139, 140
Fertility treatment, 59
“First-order” and “second-order” decisions, 20–21
Formulary committees, 105–106, 119, 121, 147–148
Fowler, E. J. et al., rating study, 58–59
Framing effects, 91, 93
Free market allocation of health care. See Market rationing
“Futility” debate, 178–179
“Fuzzyness” or confusion, 12, 22, 29f
Gene therapy, 38
Greed, 120

Hadorn, David, 75–76
and Robert Brook, 23, 24–26
Hastings Center, 32
Health care decisions, 74, 93. See also Physicians’ decisions
as “tragic choices,” 20–21
Health care industry. See also Insurance companies; Managed care organizations; Medical institutions;
Physician group practice
labor intensive, 38
salary-based systems, 140
Health care rationing. See also Bedside rationing; Cost-effectiveness analysis (CEA); Market rationing
debate over necessity of, 33–34, 35, 173
defining, 2, 11–12, 28–30, 29f
distinguishing between necessary and beneficial treatment, 24–30, 29f
explicit vs. implicit definitions, 1, 10, 13, 14f, 15f, 16–19, 17f, 29, 75t
“fuzzyness” or confusion in, 12, 22, 29f
politics and, 11–13
problems with restrictive definitions, 16, 19, 22, 24–28, 28
whether including nonhealth care products, 34–37
withholding beneficial or discretionary treatment, 15f, 23, 42–43, 45
withholding necessary treatment, 13–14, 14f, 15f, 24f
withholding scarce vs. non-scarce resources, 13, 14f, 15f, 19–22, 20f, 23–24, 81–82, 118, 121–122
global rules vs. bedside rationing, 147–150
viewed as a necessity, 3, 4, 5, 31, 33–37
Health care treatment. See Treatment (medical)
Health utility maximization. See also Cost-effectiveness analysis (CEA); Utility assessment
Healthcare industry.
Health care treatment. See Treatment (medical)
Health utility maximization. See also Cost-effectiveness analysis (CEA); Utility assessment
Heart conditions and treatments
artificial hearts, 38
congestive heart failure, 22–23, 180
coronary screening tests, 129–130
heart attack, 112
heart bypass surgery, 19, 108
heart pain (angina), 78
HIV infection, 59, 78, 173, 174, 182
Howard, Coby, 3–4, 18, 22, 46
Hypertension, 114
Hysterectomy, 37, 108
Illness, nature of, 57. See also Severity of illness; and by disorder
Implicitness, 113. See also Explicitness
cost-effectiveness as implicit rationing, 125–129, 134–134
vs. explicitness in defining rationing, 1, 10, 13, 14f, 15f, 16–19, 17f, 29, 75t
Information on health care options, 44–45, 135
Informed consent, 181
Innumeracy, 91–92
Insurance companies, 44, 91. See also Insurance, health; Reimbursement decisions;
Third-party payers; Utilization reviews
case managers, 106
Insurance, health. See also Discretionary services; Insurance companies;
Moral hazard; Uninsured or underinsured people
basic benefits packages, 27, 174
benefits of risk-spreading, 41–42, 43
impacts on cost of health care, 32
linking with employment, 21
risk-sharing leads to excess demand, 31, 40
uninsured or underinsured people, 28, 39
Insurance study (Rand), 42–43
Intensive care (ICU) treatment, 178–180
public’s prioritizing of, 179
Justice, theories of, 70, 94
Kahneman, D. and C. Varey, pain pills (follow-up) study, 86, 89
Kidney transplants, 22, 62–63
Krebs cycle, 178
Laboratory tests. See Screening tests
Language. See Linguistic factors
Life saving interventions, 45, 55
cost-effectiveness undervaluing, 35t, 178
public’s prioritizing of, 55, 76–78, 77f, 156, 179
refusing, 178–179
treatment outcomes (anticipated) and, 77f
Linguistic factors, 21, 62, 73–74, 74t, 125, 129
alternative terms for physicians’ decisions, 125, 129, 135, 136
Liver transplants, 16, 22
Longevity, 36
Loewenstein, George, transplant study, 82–85
Mammography testing standards, 132–133
Managed care organizations, 21–22, 138. See also Reimbursement decisions
Market rationing, 17–19, 21, 48–49
health care based on ability-to-pay, 17–19, 21, 41–42
Mathematics of measurement. See also QALY (Quality-adjusted life-year); Studies on health care priorities
innumeracy, 91–92
Krebs cycle, 178
measurement errors, 168–169, 169f
multiplicative intransitivity, 168–169, 169f
the QALY trap, 161–163, 163f, 163–168, 164f, 165f
random distribution and, 87–88
Medical advances
cost of health care and, 32–33, 175–176, 181
new drugs, 106, 114–115, 173–176
new technologies, 32–33, 106, 107
Medical care. See Treatment (medical)
Medical institutions. See also Third-party payers
formulary committees, 105–106, 119, 121, 147–148
Medical utilitarianism, 67–68
Meno, The (Platonic dialogue), 12–13
Mill, John Stuart, theory of utilitarianism, 68
Moral hazard
defined, 40–41
insurance risk-spreading as, 31, 40
restaurant check-sharing example, 31
ways of reducing, 40, 105 (see also Insurance, health)
choosing plans at time of enrollment, 43–46
eliminating health insurance, 41–42
not covering discretionary services, 42–43
Moral values, 67, 70, 78. See also Value judgements
bedside rationing and, 101, 102, 144–145, 146–147
cost-effectiveness analysis (CEA) and, 67, 69
debates over, 10, 29, 183
MRI scanners, 20, 121–122, 130–131
“Multiplicative intransitivity,” 168–169, 169f. See also Mathematics of measurement

Narratives. See Patient care vignettes
National Cancer Institute, 132–133
Noneconomic rationing, 117–118
Nonhealth care products affecting health, 34–37
Nord disability-levels scale, 70–71, 71f
Nord, Eric, study of public values, 70–73, 71f, 74t. See also Philadelphia jurors survey

Older patients, 93
Oregon Medicaid Program, 11, 56–57, 107, 149
bone marrow transplants not funded, 3–4, 18, 22, 46
experience with cost-effectiveness analysis (CEA), 4–5, 6, 7–10, 33, 46, 47, 52, 53, 75, 161
explicitness of rationing system, 10, 19
Organ allocation survey (Ubel), 82–85
Organizational context, 180–181
Out-of-pocket costs, 105, 118–119, 181
copayments, 42–43, 144

Pain pills study, 85–86
follow-up study, 86, 89
Pap smears. See Cervical cancer screening
Paraplegia, 76–78, 77f, 161–163, 162f, 163f
Patient care vignettes
alcoholic needs transplant (socially undesirable behavior), 16–17
Andrea’s allergy (out-of-pocket expenses), 118–119
blood test for Mr. Thrifty (expensive testing), 144
brain tumor (standards of care), 130–131
case vignettes survey (Asch), 126–128
colon screening for Mr. Williams (cost of tests), 126
coronary problem of Mr. Stevens (cost of testing materials), 129–130
heart transplant dilemma, 67, 68–69
high cholesterol of Ms. Corell (trying inexpensive drugs first), 135–136
hypertension of Mr. Nye (old vs. new drug), 114–115
Joe’s heart attack (cost of drugs), 112
knee surgery for Mrs. Glenn (“best” or satisfactory care), 135
Mr. Jordan wants a PSA test, 115–116
Pap smear for Mrs. Jordan (testing protocol), 126
Peace Corps volunteer and murderer (medical ethics), 67
rectal exam for Mr. Jones (test protocols), 132
reflux problem of Ms. Lavedan (external rules), 133
reflux problem of Ms. Lavedan revisited (cost containment), 134
“soft indication” for MRI screening (Mr. Dylan), 121–122
urinary infection of Mrs. Baron (plain vs. broad spectrum antibiotic), 117–118
urinary tract problems of Mr. Olsen (cost of testing materials), 120

Patient-doctor relationship. See Physician-patient relationship

Patients’ decisions
ability-to-pay and, 17–19, 21, 41–42
adverse selection and, 44
copayments, 32, 42–43, 144
out-of-pocket costs and, 105, 118–119, 181
voluntary rationing, 93, 119
Patients’ interests, 30, 134–135, 144–145
evaluating treatment from perspective of, 116
whether rationing savings benefit, 105, 110, 112, 117–120, 123/124, 130, 145–146
withholding treatment that would be, 111, 114–116, 122–123, 123f
Patients’ knowledgeability, 44–45, 135
Pediatric care, 21–22
Person trade-off method (PTO), 165, 168–169
PET (positron emission tomographic) scans, 44
Pharmaceuticals. See also by individual drug
expensive vs. inexpensive drugs, 114–115, 117–119, 121, 135–136
formulary committees determining, 105–106, 119, 121, 147–148
new drugs, 106, 114–115, 173–176
Philadelphia jurors survey (Ubel), 73–74, 74f
Physical therapy, 36
Physician decisions, standards of care and, 130–131
Physician group practice, 155
Physician-patient relationship, 22, 143. See also Patients’ decisions; Patients’ interests; Physicians’ decisions
trust factor, 102–103, 139–143
Physicians’ decisions, 22, 95. See also Bedside rationing
administrative hoops and, 133–134
advocacy role, 101–102, 109, 112–113, 138–139, 147–148
alternative terms for, 125, 129, 135, 136
degree of control over resources, 112, 120–122, 123f, 124
external rules and, 133–134
legal protection for, 131
medical vs. value judgements, 127–128, 128f
Physician training, 103, 109, 118, 143–144, 178
Plato, 12–13
Political processes, 49–50
in defining health care rationing, 11–13
revealing community values, 48
Populations
entire vs. partial coverage of, 87–88, 89–91, 90f
statistical groups vs. individuals, 35–36, 92–93, 180
Practice guidelines, 107–108
Preventive care, public preference for, 57, 72
Preventive Services Task Force, U.S., 132
Price reduction, 37–40
Prognosis. See Treatment outcomes
Prostate surgery, 37
Protease inhibitors, 173, 174
Proton pumps, 147–148, 150
Public health objectives, 117–118
Public Health Service, U.S., 171
Public’s health care priorities, 28, 47, 55–56, 74, 140, 182. See also Cost containment; Fairness; Life-saving interventions; Preventive care; Severity of illness; Treatment outcomes
confusion in or difficulty interpreting, 48–50, 86, 155–156, 168–169, 169f
cost-effectiveness analysis not reflecting, 35f, 47–50, 53–56, 55f, 55–56, 85, 155, 156, 172, 178
measurement of (see also Framing effects; Linguistic factors; Mathe-
Public's health care priorities (cont.)
    mathematics of measurement; Studies on health care priorities
    assessing willingness to pay, 60–61
direct vs. indirect valuation, 168–169, 169f
    ranking methods, 56–58
    rating methods, 58–60
    statistical populations vs. individual scenarios, 35–36, 92–93, 180
    utility-elicitation, 50–51
    subconscious influences, 62–64
Public values, Nord study of, 70–73, 71f, 74t
QALY (Quality-adjusted life-year), 8–9, 51, 53–54, 156–157, 159–161
    CEA measurement, 8–9, 51, 53–54, 65
    incorporating preferences, 159–161, 163–168, 164f, 165f
    measurement errors, 168–169, 169f
    the QALY trap, 161–163, 163f, 163–168, 164f, 165f
Quality-of-life, 157. See also Treatment outcomes
    judgements about patients’, 179–180
    public priorities regarding, 57
Racial factors, 62–63, 85, 103–104.
    See also Discrimination
Radiology testing, 11–12, 27, 142
    contrast agents, 120, 129–130
Rand health insurance study, 42–43
Rationing decisions, public. See Public’s health care priorities
Rationing. See Bedside rationing;
    Cost-effectiveness analysis (CEA);
    Health care rationing
Rawls, John, 182
Reimbursement arrangements
    capitation payments, 107, 109, 120, 177
    fee-for-service, 109, 139, 140
Reimbursement decisions, 105–106
Rescue, rule of, 76
Restaurant story, 31. See also Moral hazard
    Rule of rescue, 76
Screening tests, 23, 44, 109, 126, 150
cervical cancer screening, 5–6, 131, 141–142
colon cancer screening, 23, 24–26, 37–38, 141
coronary, 129–130
MRI scanning, 20, 121–122, 130–131
Self-interest, 73–74, 74f
    Severity of illness, 74t, 75t
    cost-effectiveness analysis and, 161–162
    public’s prioritizing of, 56, 69–71, 71–76, 74t, 75t, 85, 156
Sigmoidoscopy. See Colon cancer screening
Socially unacceptable behavior, 16–17, 182
Societal financial interests, 129–130
Societal values. See also Public’s health care priorities
    incorporating into CEA measures, 157, 161, 163f, 163–169, 164f, 165f
    patients’ collective interests, 145
    public health objectives, 117–118
Society of Medical Decision Making, 79
Socioeconomic factors, 103. See also
    Ability to pay; Out-of-pocket costs
Socrates, 12–13
Standards of care, 130–131
Standards of evidence, 132–133
Statistical populations vs. individuals, 35–36, 92–93, 180
Statistical vs. individualized decisions, public preference and, 35–36
Stories. See Patient care vignettes
Studies on health care priorities
bioethics group members study (Ubel), 79–81
blood test study, 93
case vignettes survey (Asch), 126–128
colon cancer screening vignette (Ubel), 79–81, 81f, 87–91, 88f, 90f
critical care professionals study, 56, 57
Fowler et al. rating study, 58–59
Nord study of public values, 70–73, 71f, 74t
pain pills follow-up study (Kahneman and Varey), 86, 89
Philadelphia jurors survey (Ubel), 72, 73–74, 74t
Rand health insurance study, 42–43
transplant study (Loewenstein), 82–85
utility assessment study (Ubel), 53–56, 54t, 55t, 70
Suicidal patients, 59
Sulmasy, Dan, 119–120
Surgery, 37. See also Transplants; and by procedure
Survival probability, 56, 57, 82–83, 92
Technologies, new. See Medical advances
Third-party payers, 45, 105, 110, 121, 138, 174. See also Administrative rationing mechanisms
bedside rationing and, 150–151, 176–177
responding to medical advances, 175–176
TMJ (temporomandibular joint)
splints, 52
Tonsillectomy, 37
“Tragic choices,” 20–21
Transfusions, 179–180
Transplants
allocation of scarce organs, 22, 81–85, 118
blood test vignette study, 93
bone marrow, 107
bone marrow (Coby Howard story), 3–4, 18, 22, 46
kidney, 62–63
liver, 22
retransplants, 85
Transplant study (Loewenstein), 82–85
Treatment (medical), 18, 33–34, 35–36, 55. See also Life saving interventions; Medical advances; and by technology or intervention
alternative characterizations of, 125, 129, 135, 136
distinguishing between necessary and beneficial, 14f, 15f, 24–30, 27–28, 29f, 43, 45, 177
marginal or infinitesimal benefits, 108, 148–149, 177–178
Treatment outcomes, 30, 72–76, 83, 118. See also Quality-of-life factored in CEA, 7, 15–158
improving disability levels, 71f
reversibility of disorder, 57
survival probability, 56, 57, 82–83, 92
Treatment. See Treatment (medical)
Triage policies, 70
Trust between patient and physician, 102–103, 139–143. See also Physician-patient relationship
Ubel, Peter A., and colleagues
bioethics group members study, 79–81
cervical cancer screening vignette, 126–128, 128f
colon cancer screening vignette, 79–81, 81f, 87–91, 88f, 90f
organ allocation survey, 82–85
Philadelphia jurors’ survey, 72, 73–74, 74t
Ubel, Peter A. (cont.)
utility assessment study, 53–56, 54–70, 55
Ulcer treatments, 147–148, 150
Uninsured or underinsured people, 28, 39
United Kingdom, 177
Urinary tract problems, 117, 120
Utilitarianism, medical, 67–68. See also Cost-effectiveness analysis (CEA)
Utility assessment, 64–65, 70
aggregate nature of, 57–58
health utility maximization goal, 55–56, 78–79, 85
not predictive of rationing decisions, 53–56, 55–70
person trade-off method (PTO), 165, 168
Utility assessment study (Ubel), 53–56, 54–70
Utility-elicitation methods, 50–51
standard gamble method, 52, 54–70
utility rating scale, 51–52, 54–55
Utilization reviews, 45, 105, 106, 110, 121, 177

Value judgements, 27, 94. See also Framing effects
about patients’ quality-of-life, 179–180
in determining necessary (vs. beneficial) treatment, 24–30, 29/
Veatch, Robert, 112–113
Veterans Administration (VA) system, 106, 140–141, 181
Viagra, 106, 174

Wasteful practice elimination, 11, 37–40, 115
Wording. See Linguistic factors

Yaari, M. E., and M. Bar-Hillel (1991), pain pills study, 85–86